van de Wakker Simonides I, Fischer Marcel J E, Oosting Ronald S
Division of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands.
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands.
Eur J Pharmacol. 2017 Aug 15;809:178-190. doi: 10.1016/j.ejphar.2017.05.038. Epub 2017 May 19.
The influenza virus (IV) is a highly contagious virus causing seasonal global outbreaks affecting annually up to 20% of the world's population and leading to 250,000-500,000 deaths worldwide. Current vaccines have variable effectiveness, and, in particular during a pandemic outbreak, they are probably not available in the amounts needed to protect the world population. Therefore we need effective small molecule drugs to combat an IV infection and that can be produced, in case of pandemic, rapidly and in large quantities. Unfortunately, natural occurring IV becomes more and more resistant to current anti-IV drugs. And thus, there is an urgent need for development of alternative agents with new mechanisms of action. This review provides an overview of the pharmacology and effectiveness of new anti-IV agents, focusing on inhibition mechanisms directed against virus-host interactions.
流感病毒（IV）是一种极具传染性的病毒，会引发全球性季节性疫情，每年影响全球多达20%的人口，并导致全球25万至50万人死亡。目前的疫苗有效性各异，尤其是在大流行期间，可能无法提供足以保护全球人口所需数量的疫苗。因此，我们需要有效的小分子药物来对抗IV感染，并且在大流行时能够迅速大量生产。不幸的是，天然存在的IV对当前的抗IV药物越来越耐药。因此，迫切需要开发具有新作用机制的替代药物。本综述概述了新型抗IV药物的药理学和有效性，重点关注针对病毒-宿主相互作用的抑制机制。
